Journal of Innovations in Applied Pharmaceutical Science [JIAPS]

Content available at: www.saap.org.in ISSN: 2455-5177

AI IN PHARMACEUTICAL ANALYSIS: A COMPREHENSIVE REVIEW

RAJASEKHAR YELURI[1], SUSHMA ANDIBOINA[1], GANESH GORLE[1], LAXMI PRASANNA SIMHADRI[1], V. SRINIVASA RAO[1], RAMAIAH MADDI[2]

[1]*Department of Pharmaceutical Analysis, Maharajah's College of Pharmacy, Phool Baugh, Vizianagaram – 535002, A.P., India*

[2]*Department of Pharmacognosy, Maharajah's College of Pharmacy, Phool Baugh, Vizianagaram – 535002, A.P., India*

DOI: https://doi.org/10.37022/jiaps.v11i1.818

Article History

Received: 17-02-2025
Revised: 08-03-2025
Accepted: 18-04-2026

Keywords: Artificial intelligence; Pharmaceutical analysis; Machine learning; Deep learning; Chromatography; Spectroscopy; Mass spectrometry; Process analytical technology; Green analytical chemistry; Quality control.

***Corresponding Author**
Dr. Ramaiah Maddi

Abstract

Artificial intelligence (AI) is rapidly transforming pharmaceutical analysis by shifting conventional analytical practice from labor-intensive, trial-and-error methods toward faster, data-driven, and predictive approaches. The increasing complexity of pharmaceutical formulations and the large volume of data generated by modern analytical instruments have created a strong need for intelligent computational tools capable of accurate interpretation and decision-making. In this context, AI, particularly machine learning and deep learning, has emerged as a powerful support system in pharmaceutical analysis. Its applications extend across chromatographic analysis, spectroscopic techniques, and mass spectrometry, where it improves pattern recognition, peak analysis, classification, prediction, and method optimization. AI also contributes significantly to pharmaceutical quality control, process analytical technology, and real-time monitoring by enabling automation, anomaly detection, and predictive maintenance. In addition, AI supports the principles of green analytical chemistry by helping reduce solvent consumption, optimize experimental design, and improve sustainability in analytical practices. This review presents a comprehensive overview of the role of AI in pharmaceutical analysis, highlighting its major applications, benefits, current challenges, and future prospects in advancing accuracy, efficiency, and innovation in the pharmaceutical sector.

1. INTRODUCTION

Pharmaceutical analysis plays a critical role in ensuring the safety, efficacy, and quality of drug products. It involves the identification, quantification, and characterization of active pharmaceutical ingredients, impurities, degradation products, and excipients in raw materials and finished formulations. With the increasing complexity of modern pharmaceutical products, including multi-component formulations, biologics, and personalized medicines, traditional analytical approaches often face limitations in terms of speed, sensitivity, data handling, and interpretation.

The growing demand for high-throughput screening, real-time monitoring, and precise quality assessment has further challenged conventional analytical techniques. Modern analytical instruments such as chromatography, spectroscopy, mass spectrometry, and imaging platforms generate vast and complex datasets that require advanced tools for effective interpretation. In this context, artificial intelligence (AI) has emerged as a transformative technology in pharmaceutical analysis.

AI, including machine learning, deep learning, and other data-driven computational approaches, enables rapid processing and interpretation of large volumes of analytical data. It offers powerful capabilities for pattern recognition, predictive modeling, method optimization, anomaly detection, and automated decision-making. By integrating AI with pharmaceutical analytical workflows, researchers and industry professionals can improve accuracy, reduce human error, accelerate analysis, and enhance overall efficiency.

As the pharmaceutical industry moves toward digitalization and smart manufacturing, AI is becoming increasingly important in analytical science. Its applications are expanding across drug development, quality control, process analytical technology, impurity profiling, and stability studies. This review provides a comprehensive overview of the role of AI in pharmaceutical analysis, highlighting its principles, applications, advantages, challenges, and future prospects.

2. OVERVIEW OF ARTIFICIAL INTELLIGENCE

Artificial Intelligence in the pharmaceutical industry is a cutting-edge computational technology intended to replicate various cognitive aspects of the human brain, including learning, thinking, and problem-solving, to address the significant complexities of pharmaceutical research. Instead of functioning as a straightforward machine, AI is an advanced decision support system with the ability to integrate and interpret multidimensional biological data sets, including genomics, proteomics, and transcriptomics, to detect new

pharmaceutical targets with a high degree of precision [3, 15]. Apart from target discovery, AI algorithms play a significant role in optimizing various analytical processes by improving high-throughput screening, predicting molecular stability, and calibrating sophisticated instruments including HPLC and Mass Spectrometry instruments [1, 30]. From a simple observation-based approach to a sophisticated prediction-based approach, AI is improving the speed and accuracy of pharmaceutical analysis, including aspects of safety and efficacy, to ensure that pharmaceutical analysis meets high standards with a significant degree of accuracy [24, 27].

3. MACHINE LEARNING (ML) IN PHARMACEUTICAL ANALYSIS

Machine Learning (ML) serves as a "high-performance engine" for the execution of multivariate data analysis, allowing for the discovery of non-linear patterns in large volumes of chemical and biological data. In modern pharmaceutical analysis, supervised ML algorithms, specifically Random Forests (RF) and Support Vector Machines (SVM), have emerged as the "golden standard" for predicting the bioactivity of small molecules during early-stage lead optimization studies [4, 6]. The algorithms, based on molecular descriptors, allow for Quantitative Structure Activity Relationship (QSAR) modelling, thus avoiding costly "wet-lab" iterations through the in-silico prediction of a small molecule's pharmacological profile [2, 10]. Moreover, ML has also begun to be used for the rapid classification of impurities, as well as "out of specification" (OOS) result prediction based on historical stability data, with chromatographic data being used as an input [1, 15]. The shift from "descriptive" observation to "predictive" forecasting with ML eliminates human error, thus greatly improving the overall robustness of quality assurance procedures.

4. DEEP LEARNING (DL) IN PHARMACEUTICAL ANALYSIS

Deep Learning (DL) is a highly advanced and evolved concept in the field of machine learning, which has completely changed the way unstructured 'Big Data' is analysed in the pharmaceutical sciences. DL architectures, such as the Convolutional Neural Networks (CNNs), have been designed and optimized for the analysis and inspection of high-resolution images, which is currently being used to perform quality control inspections, such as the analysis of tablet coatings and microscopic surface features, with much more accuracy than the human eye [13, 14]. However, the complexity of biological sequences is now being decoded using architectures such as the Recurrent Neural Networks (RNNs) and the latest in sequence analysis using the Nucleotide Transformer, a highly advanced DL architecture [4]. These architectures have the ability to quickly identify long-range dependencies in multi-omics sequences, which is allowing the quick mapping of genomic sequences and proteomics, leading to the identification and analysis of drug resistance and response using these architectures [3, 26]. This is leading the field of pharmaceutical analysis towards a highly automated state, where the gap between biological sequences and clinical analysis is being bridged using DL architectures [15, 23].

5. CHEMOMETRICS AND DATA ANALYSIS

AI-aided chemometrics has, therefore, far transcended classical linear regression analysis. Instead, it has developed into a sophisticated field of study, where cutting-edge generative models are used to address the inherent complexities of chemical information. The field of chemometrics today includes Variational Auto encoders and Generative Adversarial Networks for generating realistic analytical datasets [3.2, 7]. The generative approach is particularly significant in pharmaceutical applications where physical samples are either scarce, expensive, or difficult to synthesize. The AI-aided chemometric approach offers a potent solution for generating realistic datasets for improving the performance of analytical models. By employing AI-aided chemometric approaches, researchers can effectively carry out multivariate spectral deconvolution and denoising of signals in complex multi-component formulations, where classical statistical approaches are unable to capture non-linear variances. The AI-aided chemometric approach is not only improving the accuracy of analytical methodologies but is also enabling researchers to develop "digital reference standards." This is paving the way for developing robust and flexible quality control approaches in the era of "Pharma 4.0" [1, 30].

6. AI TECHNIQUES USED IN PHARMACEUTICAL ANALYSIS

The practical application of AI in pharmaceutical analysis is strategically divided into three main learning paradigms, each designed to address a unique problem. Supervised Learning algorithms have been found to be the most widely used, particularly for the quantitative analysis of intricate formulations, where they are used to predict the exact concentration of Active Pharmaceutical Ingredients (APIs) within intricate multi-component mixtures [5, 17]. Conversely, Unsupervised Learning offers a robust platform for exploratory data analysis, where algorithms are used to identify subtle "out-of-trend" (OOT) results within long-term stability testing by applying clustering and dimensionality reduction techniques, effectively flagging anomalies within a data set that might otherwise go unnoticed through statistical analysis alone [1, 21]. The recent discovery of Reinforcement Learning (RL) is paving the way for autonomous laboratories. By applying RL to optimize the iterative "Design-Make-Measure" process, researchers are able to greatly reduce the time necessary for validation, effectively creating self-correcting analytical tools that evolve with real-time feedback [9, 22]. These approaches are used to bridge the gap between raw analytical results and high-level regulatory compliance [2, 29].

7. AI IN CHROMATOGRAPHIC ANALYSIS

The convergence of Artificial Intelligence and separation sciences has ushered in the era of "Unified AI-assisted Chromatography," a paradigm shift where computational intelligence directs the physical separation process [15, 28]. This integration has fundamentally transformed chromatographic workflows by automating highly complex tasks that were previously reliant on human expertise. Specifically, AI-driven algorithms now achieve superior Peak

Deconvolution, utilizing deep learning to resolve co-eluting or overlapping peaks in intricate matrices, such as complex herbal formulations or multi-API products [5, 16]. Furthermore, the application of machine learning for Retention Time Prediction has reached a level of maturity where molecular descriptors can be used to forecast elution profiles with high accuracy, often eliminating the need for preliminary "wet-lab" scouting runs [19, 21]. Beyond mobile phase optimization, advanced algorithms facilitate Column Selection by correlating chemical structure-polarity relationships with extensive stationary phase databases, thereby suggesting the most efficient column type for a given separation [5, 17]. These AI-enhanced capabilities collectively minimize solvent consumption and drastically reduce the time-to-market for new pharmaceutical entities [1, 9].

8. AI IN SPECTROSCOPIC ANALYSIS

Spectroscopy, as a discipline, is in the midst of a "State of the Industry" transition, where the fusion of AI technology has resulted in the evolution of the process from a "slow, destructive process to a rapid, non-destructive diagnostic process" [7, 12]. Thus, the pharmaceutical industry can now utilize the benefits of AI, specifically designed for Near-Infrared and Raman Spectroscopy, to conduct "through-packaging analysis" of raw materials, which can ensure the identity and purity of the material without compromising the sterile integrity of the packaging material [8, 17]. This process can now be further optimized through the "rewrite" of the existing process of interpreting the results of vibrational nanoscopy, which has been made possible through the implementation of Generative AI, where "accurate maps" can now be generated from "sparse or noisy data points" [7, 11]. Thus, the fusion of AI and Spectroscopy not only ensures the optimization of the quality assurance process but also provides the basic framework for the creation of a "digital twin" in the continuous process scenario [2, 10].

9. AI IN MASS SPECTROMETRY (MS)

The long-standing bottleneck of Mass Spectrometry (MS) analysis, which has traditionally involved the labour-intensive interpretation of complex data, is now being systematically addressed through the integration of Artificial Intelligence. As of 2025-2026, Machine Learning (ML) models have now become indispensable for de novo peptide sequencing, facilitating the direct sequencing of amino acid chains from tandem mass spectra without the need for a corresponding protein database [12, 18]. Furthermore, deep learning algorithms have now been employed to predict precise fragmentation patterns for unknown metabolic impurities and degradation products, a development that has significantly reduced the industry's traditional reliance on extensive physical libraries of reference materials [2, 22]. By using high-resolution mass-to-charge (m/z) values to correlate with topology, AI models can now propose chemical structures for unknown molecules with high degrees of certainty, a development that has significant implications for the analysis of biologics and the sensitivity of impurity profiling in regulated pharmaceutical environments [10, 15, 16, 23].

10. AI IN PHARMACEUTICAL QUALITY CONTROL (QC)

However, in the context of Pharma 4.0, Artificial Intelligence has redefined the operational efficiency of Quality Control (QC) laboratories by shifting from a reactive to a proactive management of analytical instrumentation. The most common application of this paradigm has been the Predictive Maintenance of QC instrumentation, whereby AI algorithms specifically designed for this purpose monitor real-time data generated by internal sensors of high-performance liquid chromatography (HPLC) and mass spectrometry (MS) instrumentation [5, 21]. These algorithms, by analysing slight changes in pressure profiles or baseline noise, can accurately forecast pump seal failures, column clogging, or lamp degradation before a complete system breakdown [1, 13]. This predictive maintenance ensures zero downtime in QC laboratories, thereby eliminating the risk of losing precious stability samples and costly analytical runs [10, 20]. The AI-based QC frameworks also incorporate data integrity tests, whereby Deep Learning algorithms detect "out of trend" (OOT) deviations and peak inconsistencies with a level of accuracy and sensitivity that cannot be achieved by conventional means [6, 14]. The marriage of AI and QC instrumentation, therefore, not only ensures improved regulatory compliance but also facilitates the streamlined release of life-saving pharmaceutical products by providing a more resilient and self-diagnostic QC infrastructure [2, 17].

11. AI IN GREEN ANALYTICAL CHEMISTRY (GAC)

The prioritization of Green Analytical Chemistry (GAC) has emerged as a "regulatory and ethical imperative" in the pharmaceutical industry, with the goal of drastically reducing the amount of toxic waste generated and the consumption of hazardous reagents [11, 14]. Artificial Intelligence plays an important role in this "sustainable shift" in the pharmaceutical industry, where the focus has changed from "empirical experimentation" to "predictive modelling." Artificial Intelligence algorithms, for example, help in "Solvent Minimization" to accurately predict the "minimum amount of solvent" required for a particular separation, thus avoiding the "unnecessary disposal of solvent waste" [12, 19]. Moreover, Artificial Intelligence incorporates "highly sophisticated" Digital Assessment tools, such as the AGREE calculator and the RGB-12 model, to "quantify the 'green' impact" of an analytical method "in silico" [9, 11]. Such a "Green-by-Design" shift in the pharmaceutical industry not only helps in achieving the "sustainability objectives" of the world but also improves the "cost-effectiveness" of pharmaceutical R&D, as the "cost of hazardous waste management" is drastically reduced [12, 21].

13. AI IN PAT AND REAL-TIME MONITORING

Artificial Intelligence serves as the essential "computational brain" of Process Analytical Technology (PAT). It changes static manufacturing into a flexible, smart system. By continually examining high-frequency, in-line data from sensors, particularly Near-Infrared (NIR) and Raman spectroscopy, AI models create accurate Digital Twins of the entire manufacturing workflow [1, 15]. These digital replicas mimic the physical process in real-time. This allows the system to

spot small variations in moisture content, blend uniformity, or particle size distribution as they happen [17, 21]. Importantly, this AI-driven monitoring supports Real-Time Monitoring and independent feedback loops. The system can make immediate changes to critical process parameters, like tablet compression force or granulation spray rates, without stopping the production line [13, 18]. This move away from traditional "batch-and-test" methods to continuous, self-correcting manufacturing greatly lowers the risk of batch failures and helps maintain consistent product quality. It ultimately fits with the regulatory goal of Quality by Design (QbD) for the modern pharmaceutical industry [2, 10].

14. BENEFITS OF AI IN PHARMACEUTICAL ANALYSIS

AI greatly improves pharmaceutical analysis by moving the industry from reactive, manual processes to proactive, high-throughput systems. By integrating machine learning into routine testing, laboratories can almost eliminate the risks of human error and fatigue. This ensures that quality control stays consistent even with large datasets [19]. In addition to making operations more efficient, AI is crucial for Precision Medicine. It has the unique computational power needed to synthesize complex multi-omics data, like genomics and metabolomics [21]. This enables a detailed understanding of a patient's biological makeup. Researchers can then shift away from generic treatments and design customized drug dosages that maximize effectiveness while reducing the chance of negative side effects [22].

15. CHALLENGES AND LIMITATIONS

Integrating AI into the pharmaceutical sector faces significant challenges. These issues mainly stem from a growing AI skills gap and the complexity of advanced algorithms. The current workforce often lacks the specific data science training needed to validate and manage complex AI models in laboratory settings [4.4]. This shortage of skilled workers is made worse by the "Black Box" nature of Deep Learning (DL) architectures. These models often reach conclusions using millions of non-linear parameters, which means they lack the transparency necessary for important clinical validation. As a result, regulatory bodies like the FDA take a cautious approach. Safety-critical decisions in drug development require a high level of understanding and traceability, which current DL models find difficult to offer [2.3, 4.3].

Table 1: Future Changes in of AI with Pharma and Regulatory Departments

Challenge	Impact on Pharma	Regulatory Requirement
Skills Gap	Inability to audit or maintain AI systems.	Qualified personnel for GLP/GMP compliance.
Interpretability	Unclear why a specific drug candidate was chosen.	Explainable AI (XAI) for safety assurance.
Data Bias	Potential for skewed results in diverse populations.	Representative and unbiased clinical datasets.

16. Future Perspectives

By simulating molecular interactions at an atomic level of detail that is still beyond the capabilities of classical computers, the integration of Quantum Machine Learning (QML) is predicted to revolutionize pharmaceutical analysis by 2026 [4.1]. The "approximation gap" that presently impedes drug discovery can be eliminated thanks to this increase in computational power, which enables researchers to model intricate electronic structures and protein folding with nearly perfect accuracy [1.5, 3.6]. The industry is moving toward "Closed-Loop Discovery," an autonomous R&D model where AI-driven platforms create, synthesize, and test new compounds in a continuous, self-optimizing cycle [2.1]. It is anticipated that these intelligent systems will shorten discovery timelines from years to months as they move from pilot to regular use, setting a new benchmark for accuracy and speed in global health [1.5, 3.2].

Table 1: Future Changes in AI with Quantum Enhance Technology Beniits Comparison

Feature	Classical AI (Pre-2026)	Quantum-Enhanced AI (2026+)
Simulation Depth	Molecular approximations	Atomic/Electronic precision
Workflow	Linear & Human-dependent	**Closed-Loop & Autonomous**
Timeline	4–6 years for candidates	18 months or less
Key Advantage	Pattern recognition in big data	Simulation of fundamental physics

17. CONCLUSION

AI is now the essential framework for pharmaceutical analysis in the future; it is no longer an add-on. The shift is irreversible, despite the fact that there are still substantial skill-based and regulatory obstacles, especially with regard to model transparency and the "AI skills gap". A more effective, accurate, and sustainable drug development lifecycle is ensured by the move toward high-throughput, autonomous systems. Pharmaceutical research is ultimately transformed from a trial-and-error process into a data-driven science that can deliver life-saving therapies with previously unheard-of speed and personalization through the integration of AI and eventually Quantum Machine Learning

18. ACKNOWLEDGEMENT

Not Declared

19. FUNDING

Nil

20. CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest.

21. INFORM CONSENT AND ETHICAL CNSIDERATIONS

Not applicable

22. AUTHOR CONTRIBUTIONS

Both are contributed equally.

23. REFERENCES

1. Sarkar, C., Das, B., Rawat, V. S., Wahlang, J. B., Nongpiur, A., Tiewsoh, I., Lyngdoh, N. M., Das, D., Bidarolli, M., & Sony, H. T. (2023). Artificial intelligence and machine learning technology driven modern drug discovery and development. *International Journal of Molecular Sciences*, *24*(3), 2026. https://doi.org/10.3390/ijms24032026.
2. Preethi Mahalingaswamy, Venkatalakshmi Ranganathan, Sasikala Chinnappan. An Overview of Role of Machine Learning in Drug Discovery. Research Journal Pharmacy and Technology. 2026;19(3):1409-4. doi: 10.52711/0974-360X.2026.00203.
3. Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharmaceutics*, *15*(7), 1916. https://doi.org/10.3390/pharmaceutics15071916.
4. Dalla-Torre, H., Gonzalez, L., Mendoza-Revilla, J., Carranza, N. L., Grzywaczewski, A. H., Oteri, F., Dallago, C., Trop, E., De Almeida, B. P., Sirelkhatim, H., Richard, G., Skwark, M., Beguir, K., Lopez, M., & Pierrot, T. (2024). Nucleotide Transformer: building and evaluating robust foundation models for human genomics. *Nature Methods*, *22*(2), 287–297. https://doi.org/10.1038/s41592-024-02523-z.
5. 5.Liu, C., & Mo, F. (2025). Automation and AI-Powered prediction in chromatographic separation. *Accounts of Chemical Research*, *59*(1), 138–150. https://doi.org/10.1021/acs.accounts.5c00677.
6. Suriyaamporn, P., Pamornpathomkul, B., Patrojanasophon, P., Ngawhirunpat, T., Rojanarata, T., &Opanasopit, P. (2024). The Artificial Intelligence-Powered New Era in Pharmaceutical Research and Development: A review. *AAPS PharmSciTech*, *25*(6), 188. https://doi.org/10.1208/s12249-024-02901-y.
7. Flanagan, A. R., Dalal, D., & Glavin, F. G. (2025). Exploring generative artificial intelligence and data augmentation techniques for spectroscopy analysis. *Chemical Reviews*, *125*(13), 6130–6155. https://doi.org/10.1021/acs.chemrev.4c00815.
8. Liu, Y., Wu, Y., Wang, J., Qi, J., Zhou, C., & Xue, Y. (2026). Recent Advances in Raman Spectral Classification with Machine Learning. *Sensors*, *26*(1), 341. https://doi.org/10.3390/s26010341.
9. Saidatri Arige, Lakshmana Rao Atmakuri, and Rishita Mantada, (2026), Agree in Green Analytical Chemistry: from Principles to Practice, Clinical Reviews and Case Reports, 5(1); DOI:10.31579/2835-7957/157.
10. 10.Yadav, S., Chandra, H., Tiwari, K. S., Bharty, M. K., Chandravanshi, R., Chauhan, D. S., & Quraishi, M. A. (2025). A review on the role of artificial intelligence and data science in green and sustainable chemistry: current trends and futuristic pathways. *Discover Chemical Engineering*, *6*(1). https://doi.org/10.1007/s43938-025-00104-w.
11. Ahmed, S. J. a. a. D. S. H. M. H. M. G. (2026). Role of Artificial intelligence in green Analytical Technique. *Zenodo (CERN*
12.
13.
14.
15. *European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.18835001.
16. Adhao, V., Ambhore, J., & Chaudhari, S. (2025). Transforming pharmaceutical quality assurance and validation through artificial intelligence. *Artificial Intelligence in Health*, *3*(1), 18. https://doi.org/10.36922/aih025160032.
17. Gatto, A., Aloisi, V., Accarino, G., Immorlano, F., Chiarelli, M., & Aloisio, G. (2022). An artificial neural Network-Based approach for predicting the COVID-19 daily Effective Reproduction Number RT in Italy. *AI*, *3*(1), 146–163. https://doi.org/10.3390/ai3010009.
18. Park, C. S., Kang, M., Kim, A., Moon, C., Kim, M., Kim, J., Yang, S., Jang, L., Jang, J. Y., & Kim, H. H. (2023). Fragmentation stability and retention time-shift obtained by LC-MS/MS to distinguish sialylated N-glycan linkage isomers in therapeutic glycoproteins. *Journal of Pharmaceutical Analysis*, *13*(3), 305–314. https://doi.org/10.1016/j.jpha.2023.01.001.
19. Shah, R., Jaramillo, R., Thomas, G., Rayhan, T., Hossain, N., Kchaou, M., Profito, F. J., & Rosenkranz, A. (2025). Artificial Intelligence and Machine Learning in Tribology: selected case studies and overall potential. *Advanced Engineering Materials*, *27*(23). https://doi.org/10.1002/adem.202401944.
20. Uriti, S. V. (2025). A review on progress and potential of machine learning and AI in pharmaceutical development. *Journal of Pharma Insights and Research.*, *3*(2), 019–030. https://doi.org/10.69613/8pyky553.
21. Melnikov, A. D., Tsentalovich, Y. P., &Yanshole, V. V. (2019). Deep learning for the precise peak detection in High-Resolution LC–MS data. *Analytical Chemistry*, *92*(1), 588–592. https://doi.org/10.1021/acs.analchem.9b04811.
22. 18.Sherwani, A. K. (2025). HPLC Method Development Exploiting Artificial Intelligence: A digital transformation in pharmaceutical analysis. *African Journal of Biomedical Research*. https://doi.org/10.53555/ajbr.v28i1s.4761.
23. Franceschini, S., Autorino, M. M., Ambrosanio, M., Pascazio, V., & Baselice, F. (2024). An ultrasound prototype for remote hand movement sensing: the finger tapping case. *Sensors*, *25*(1), 123. https://doi.org/10.3390/s25010123.
24. Patel, P., Ali, M. I., & Sheth, A. (2018). From raw data to smart manufacturing: AI and semantic web of Things for Industry 4.0. *IEEE Intelligent Systems*, *33*(4), 79–86. https://doi.org/10.1109/mis.2018.043741325.
25. 21.Uddin, M., Arfeen, S. U., Alanazi, F., Hussain, S., Mazhar, T., & Rahman, M. A. (2025). A Critical analysis of Generative AI: challenges, opportunities, and future research directions. *Archives of Computational Methods in Engineering*. https://doi.org/10.1007/s11831-025-10355-z.
26. Saliev, T. (2025). Brain aging: Unlocking personalized strategies for cognitive resilience. *Brain Network Disorders*, *1*(4), 217–229. https://doi.org/10.1016/j.bnd.2025.09.002.
27. Nagpure, N., Raut, H., Kamble, S., & Rasala, T. (2025). Redefining preclinical research paradigms: AI-Driven drug discovery as a transformative approach to accelerate innovation, improve predictive accuracy, and reduce reliance on animal testing. *Journal of Drug Delivery and Therapeutics*, *15*(10), 115–128. https://doi.org/10.22270/jddt.v15i10.7394.

28. Farrant, R. D., & Lindon, J. C. (1999). 13 c NMR, Parameter Survey*. In *Elsevier eBooks* (pp. 365–371). https://doi.org/10.1016/b978-0-12-374413-5.00112-3.
29. Avsec, Ž., Latysheva, N., Cheng, J., Novati, G., Taylor, K. R., Ward, T., Bycroft, C., Nicolaisen, L., Arvaniti, E., Pan, J., Thomas, R.,

    Dutordoir, V., Perino, M., De, S., Karollus, A., Gayoso, A., Sargeant, T., Mottram, A., Wong, L. H., . . . Kohli, P. (2026). Advancing regulatory variant effect prediction with AlphaGenome. *Nature*, *649*(8099), 1206–1218. https://doi.org/10.1038/s41586-025-10014-0.
30. 26.Blanco-González, A., Cabezón, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & Garcia-Fandino, R. (2023). The role of AI in Drug Discovery: challenges, opportunities, and strategies. *Pharmaceuticals*, *16*(6), 891. https://doi.org/10.3390/ph16060891.
31. 27.Fuente-Ballesteros, A., & Zeidler, V. Z. (2026). Artificial Intelligence for Academic Text Generation in Analytical Chemistry: Current Risks, Indicators, and Perspectives toward Greener and More Sustainable Approaches. *Analytical Chemistry*, *98*(8), 5854–5864. https://doi.org/10.1021/acs.analchem.6c00352.
32. 28.Shrivastava, A. (2025). Chromatography and artificial intelligence. *International Journal of Newgen Research in Pharmacy & Healthcare*, 98–103. https://doi.org/10.61554/ijnrph.v3i2.2025.196.
33. 29.Niazi, S. K. (2025). Regulatory Perspectives for AI/ML implementation in Pharmaceutical GMP environments. *Pharmaceuticals*, *18*(6), 901. https://doi.org/10.3390/ph18060901.
34. 30.Fuente-Ballesteros, A., & Zeidler, V. Z. (2026b). Artificial Intelligence for Academic Text Generation in Analytical Chemistry: Current Risks, Indicators, and Perspectives toward Greener and More Sustainable Approaches. *Analytical Chemistry*, *98*(8), 5854–5864. https://doi.org/10.1021/acs.analchem.6c00352.